Skip to main content
Research CombinationAnti-AgingFat LossEmerging EvidenceEducational · Not medical advice

MOTS-c + SS-31: Mitochondrial Optimization

A mitochondrial-targeted combination pairing two peptides with distinct but complementary mechanisms. MOTS-c enhances glucose metabolism and AMPK signaling while SS-31 (Elamipretide) stabilizes cardiolipin in the inner mitochondrial membrane, protecting against oxidative damage. Researched in contexts of aging, metabolic dysfunction, and exercise performance.

2
Compounds
Emerging
Evidence Level
3
Research Refs
Anti-Aging
Primary Goal

Mechanism

Compound 1Longevity

MOTS-c

Mitochondria-derived signaling peptide that activates AMPK and enhances glucose uptake. Multiple studies demonstrate improved exercise capacity and metabolic health in aged models.

+
Compound 2Longevity

SS-31

Targets cardiolipin in the inner mitochondrial membrane, reducing ROS production at the source. Phase 2/3 trials for mitochondrial myopathy and heart failure.

Synergistic Effect

Dual-pathway activation

MOTS-c × SS-31

Safety Notes

MOTS-c is a mitochondria-derived peptide studied primarily in preclinical models; human clinical data is very limited. SS-31 (elamipretide) is an investigational drug currently in Phase 2/3 clinical trials for Barth syndrome and heart failure — it is not approved for any indication. Neither compound is approved for general health or anti-aging use. Long-term safety profiles for both are still being established through ongoing clinical research.

Research References

Established

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

Cell Metab 2015PMID 25738459
Established

First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics

Br J Pharmacol 2014PMID 23991888
Established

Coordinated deficiency of complex I subunits in aging context

J Gerontol A Biol Sci Med Sci 2020PMID 31588495
Browse all →

⚠ Educational Use OnlyPeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.